Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Special Drug Use Surveillance of Irribow® Tablets and Irribow® OD Tablets in Female Patients

NCT02612649 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02612649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02612649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Special Drug Use Surveillance of Irribow® Tablets and Irribow® OD Tablets in Female Patients
Lead sponsor
Astellas Pharma Inc
Phase
Observational
Overall status
Completed
Start date
October 1, 2015
Completion date
March 31, 2018
Enrollment
793 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea-predominant irritable bowel syndrome